Curis (NASDAQ: CRIS) reported Q1 EPS of ($0.30), $0.12 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $1.8 million versus the consensus estimate of $2.4 million.

For the remainder of the year, Curis expects to:

• Report initial data on the combination of fimepinostat and venetoclax regimen in patients with R/R DLBCL, including patients with DH/DE Lymphoma, in the second half of 2019.
• Report initial efficacy data from its CA-4948 dose escalation study in patients with NHL in mid-year 2019.
• Report initial efficacy data from its CA-170 Phase 1 trial in patients with mesothelioma (high VISTA expressors) in the second half of 2019.

For earnings history and earnings-related data on Curis (CRIS) click here.